
Current Price | $7.58 | Mkt Cap | $1.6B |
---|---|---|---|
Open | $7.50 | P/E Ratio | -5.15 |
Prev. Close | $7.54 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $7.27 - $7.68 | Volume | 952,892 |
52-Wk Range | $4.54 - $16.75 | Avg. Daily Vol. | 3,911,472 |
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
Current Price | $7.58 | Mkt Cap | $1.6B |
---|---|---|---|
Open | $7.50 | P/E Ratio | -5.15 |
Prev. Close | $7.54 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $7.27 - $7.68 | Volume | 952,892 |
52-Wk Range | $4.54 - $16.75 | Avg. Daily Vol. | 3,911,472 |
The best Bull and Bear pitches based on recency and number of recommendations.
Read the most recent pitches from players about RXRX.
Recs
AI driven drug discovery with potential to change medicine. This isn’t the only company doing this and they are only in trials for drug approval, however a recent investment from NVDA makes this a good speculative buy.
Find the members with the highest scoring picks in RXRX.
Tangoko (< 20) Score: +84.38
The Score Leader is the player with the highest score across all their picks in RXRX.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
askatch | < 20 | 11/2/2023 |
![]() |
5Y | $5.20 | +46.15% | +9.52% | +36.63 | 0 Comment | |
![]() |
TMFSaintCroix | 86.36 | 6/6/2022 |
![]() |
5Y | $7.31 | +4.04% | +10.58% | -6.55 | 0 Comment |
Tangoko | < 20 | 11/7/2023 |
![]() |
3M | $6.09 | +24.79% | +5.03% | -19.76 | 0 Comment | |
allforone | 70.00 | 6/8/2023 |
![]() |
5Y | $9.10 | -16.48% | +7.62% | -24.10 | 0 Comment | |
timeway | < 20 | 7/8/2022 |
![]() |
5Y | $8.82 | -13.83% | +18.55% | -32.39 | 0 Comment | |
Kentuckyfarmer | < 20 | 7/13/2023 |
![]() |
5Y | $10.91 | -30.31% | +2.45% | -32.75 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.